Transient ablation of regulatory T cells has been shown to be effective at hindering tumor growth and metastasis in murine breast cancer model. Based on our lab’s previous work, we have demonstrated that NK cells and CD8+ cytotoxic T cells were not required for the protective effect of Treg cell ablation. However, we also reported that CD4+ helper T cells and IFN-γ were required for the protective effect of Treg cell ablation. Furthermore, we observed that CD11B+ cells responded to Treg ablation therapy by up-regulating target genes of IFN-γ. Therefore, this study aimed to investigate the connection between the myeloid cell compartment and IFN-γ signaling after regulatory T cell ablation therapy. Through a combination of conditional knockout mouse models, cellular fate mapping experiments, adoptive transfers, and co-injection experiments, we demonstrated that tumor-associated macrophages (TAMs), derived from the bone marrow via CCR2/CCL2 axis, were responsible for the therapeutic effect of regulatory T cell ablation. In addition, we determined that IFN-γ signaling was required for the TAMs to mediate the protective phenotype seen after regulatory T cell ablation. Furthermore, based on our findings, we developed a genetic signature based on TAMs from treated or untreated tumors that had a predictive value for patient survival. Thus, our findings indicated a strong connection between IFN-γ release, classical activation of TAMs, and depletion of regulatory T cells, and taken together, our data could offer potential clinical strategies to mimic regulatory T cell ablation.

<p>IIn the first study, we investigated the functional implications of prolonged TLR signalling on IFN-γ mediated killing of mycobacteria by murine macrophages <i>in vitro</i>. TLR2, but not TLR4 ligation interfered with IFN-γ mediated killing of mycobacteria in macrophages. In terms of mechanisms, neither TNF nor nitric oxide (NO) production was significantly affected, and the refractoriness induced could be reversed with increasing amounts of IFN-γ In the second study, we aimed to identify immunological markers of diagnostic importance in both the respiratory tract and serum during pulmonary mycobacterial infection in mice. We found that increased levels of immunological markers in the respiratory tract, but not serum, correlated better with active mycobacterial infection in the lungs, suggesting that the immune response in the respiratory tract is more reflective of the infection status and pathology than the systemic response. Finally, we investigated the level and nature of immune responses to pulmonary mycobacterial infection in BALB/c and C57BL/6 mice, two mouse strains known to exhibit different susceptibilities to infection with several intracellular pathogens, including mycobacteria. We showed that increased susceptibility of BALB/c mice to early mycobacterial infection was associated with reduced Th1 immune responses, and increased sTNFR secretion in the lung. Moreover, BALB/c mice recruited fewer monocytes/macrophages to the lung, and although IFN-γ stimulation of infected bone marrow derived macrophages in both mouse strains resulted in induction of antimycobacterial activity, BALB/c mice had a reduced capacity to kill ingested bacteria. The work presented in this thesis provide further insight into the mechanisms involved in the host-pathogen interaction; from persistence, to the immunological processes induced by the pathogen, to susceptibility of the host to infection.</p>

IIn the first study, we investigated the functional implications of prolonged TLR signalling on IFN-γ mediated killing of mycobacteria by murine macrophages in vitro. TLR2, but not TLR4 ligation interfered with IFN-γ mediated killing of mycobacteria in macrophages. In terms of mechanisms, neither TNF nor nitric oxide (NO) production was significantly affected, and the refractoriness induced could be reversed with increasing amounts of IFN-γ In the second study, we aimed to identify immunological markers of diagnostic importance in both the respiratory tract and serum during pulmonary mycobacterial infection in mice. We found that increased levels of immunological markers in the respiratory tract, but not serum, correlated better with active mycobacterial infection in the lungs, suggesting that the immune response in the respiratory tract is more reflective of the infection status and pathology than the systemic response. Finally, we investigated the level and nature of immune responses to pulmonary mycobacterial infection in BALB/c and C57BL/6 mice, two mouse strains known to exhibit different susceptibilities to infection with several intracellular pathogens, including mycobacteria. We showed that increased susceptibility of BALB/c mice to early mycobacterial infection was associated with reduced Th1 immune responses, and increased sTNFR secretion in the lung. Moreover, BALB/c mice recruited fewer monocytes/macrophages to the lung, and although IFN-γ stimulation of infected bone marrow derived macrophages in both mouse strains resulted in induction of antimycobacterial activity, BALB/c mice had a reduced capacity to kill ingested bacteria. The work presented in this thesis provide further insight into the mechanisms involved in the host-pathogen interaction; from persistence, to the immunological processes induced by the pathogen, to susceptibility of the host to infection.

Les protéoglycannes exercent de nombreuses fonctions par le biais de leur partie protéique ou de leurs glycosaminoglycannes. La caractérisation des interactions entre les glycosaminoglycannes et des protéines a ouvert de larges champs d'applications. Dans ce cadre, deux thèmes de recherche ont été développés. <br />Premièrement, nous nous sommes intéressés à un nouveau protéoglycanne appelé endocan. La développement des capacités de production et de purification de cette macromolécule, nous a permis par différentes approches de déterminer le profil structural de sa chaîne glycannique et de sa partie protéique, mais aussi d'étudier les interactions avec plusieurs de ses partenaires protéiques dont l'interféron Γ et l'hépatocyte growth factor, impliqués respectivement dans l'inflammation et le développement tumoral. Parallèlement, une étude structurale et fonctionnelle de l'interaction entre l'interféron gamma et des glycosaminoglycannes de type héparanes sulfates a conduit au développement de mimes oligosaccharidiques obtenus par synthèse chimique. Parmi ces molécules, certaines permettent de moduler in vitro l'activité de la cytokine, et constituent une base possible pour le développement de nouveaux médicaments.

The peripheral immune system plays a role in delayed neural injury after stroke. This response originates from the spleen as splenectomy prior to middle cerebral artery occlusion (MCAO) in rats significantly reduces infarct volume in the brain. This research is based on the hypothesis that inhibiting the splenic response will reduce neurodegeneration after stroke. Studies in animals have implicated lymphocytes as the immune cell type that is detrimental following MCAO. Interferon gamma (IFNγ) has been identified as a pro-inflammatory cytokine that is also detrimental following stroke. IFNγ is important because it activates microglia and macrophages in a pro-inflammatory nature that increases neural injury following stroke. Therefore IFNγ was examined in the brain and the spleen following MCAO. IFNγ protein was elevated at 24 h in the spleen and at 72 h in the brain post MCAO. Microglia/macrophages become maximally activated at 72 h in the brain after MCAO. Splenectomy decreases the levels of IFNγ in the brain following MCAO. Systemic administration of IFNγ reversed the protective effects of splenectomy. The cellular response to MCAO was examined next because of the difference in time between the spike in IFNγ in the spleen and the delayed increase in the brain. The cellular response from the spleen was studied by labeling splenocytes five days prior to MCAO with a fluorescein dye. Tissues were examined 48 and 96 h post MCAO or sham MCAO for fluorescence. These cells were released from the spleen into circulation at 48 h post MCAO and migrated to the brain where the cells produced IFNγ at 96 h post MCAO. IFNγ appears to play a role in the splenic response to stroke. One protein that is up regulated by cells that have been activated by IFNγ, interferon-inducible protein 10 (IP-10) is part of the inflammatory cycle driven by IFNγ. IP-10 recruits more IFNγ producing T helper (Th) cells to the site of injury. IP-10 has the unique ability to attract Th1 cells, the pro-inflammatory Th cells, and inhibit Th2 cells, the anti-inflammatory Th cells. This leads to more IFNγ production as IFNγ is the signature cytokine of a Th1 response. IP-10 is significantly increased in the brain at 72 h post MCAO, similar to IFNγ expression. In the spleen IP-10 increased at 24 h and remained elevated out to 96 h following MCAO. IFNγ signaling was inhibited by utilizing an IFNγ neutralizing antibody administered beginning 24 h post MCAO. The IFNγ antibody treated group had decreased infarct volumes, IP-10 levels in the brain, and appeared to have decreased T cells in the ipsilateral hemisphere at 96 h post MCAO. Following ischemic stroke splenocytes are released into circulation and migrate to the brain. They release IFNγ to activate microglia/macrophages in a proinflammatory phenotype causing an increase in IP-10 levels. IP-10 then potentiates the Th1 driven inflammation which inhibits the Th2 response. The elevated levels of IFNγ increase neural injury following MCAO. Blocking IFNγ selectively blocks the inflammatory facet of the immune response to reduce stroke induced neurodegeneration. This leaves the other immune responses intact and able to contribute to tissue repair, regeneration, and able to respond to infections. Selectively inhibiting IFNγ signaling is a promising stroke therapeutic.

Microglia activity has been detected in Parkinson’s disease (PD) post-mortem brains and experimental animal models; however the precise interplay between microglia and dopamine neurons of the SNpc is not well understood. In the blood plasma of PD patients, our laboratory found elevated levels of interferon-gamma (IFN-γ), a proinflammatory cytokine and potent activator of microglia. Given this, we sought to untangle the immune responses relevant to PD in mice, examining IFN-γ’s involvement and signaling mechanism using an inflammatory co-culture model of microglia and midbrain neurons treated with rotenone. By means of RT-PCR, we discovered IFN-γ mRNA transcripts are produced by microglia, and this expression increases upon exposure to rotenone. We delineated IFN-γ’s signaling mechanism in co-cultures using different IFN-γ receptor deficient cells, and showed it engages receptors in an autocrine (not paracrine) manner to further microgliosis and dopamine cell loss. After exploring the innate immune response in a model of PD, we subsequently shifted focus to an in vivo system to better investigate any involvement of the delayed humoral arm of the adaptive immune system. Needing a time appropriate death paradigm, we developed a protracted low dose regimen of MPTP, which elicits dopaminergic cell death after 2 weeks of treatment. Subjected to this paradigm, Rag 2 mutant mice (deficient in both T and B cells) exhibit resistance to dopamine cell loss, microglia activation and motor impairments. Further evidence in support of immune involvement came with the resensitization of Rag2 mice to MPTP after reconstitution with WT splenocytes. Additionally, mice deficient in Fcγ receptors exhibited neuroprotection in our protracted degeneration model. Taken together, these data indicate the innate and humoral arm can modulate the microglial response to dopaminergic degeneration and may participate in Parkinson's disease.

L'interferon-γ (IFNγ) est une cytokine immunomodulatrice puissante, également dotée d'une activité antivirale. Il possède deux ligands de haute affinité : un récepteur par lequel il transmet ses signaux et des polysaccharides complexes de la famille des héparanes sulfates (HS), tous deux situés à la surface cellulaire. In vivo, la liaison aux HS permet de concentrer localement la cytokine et de réguler son activité biologique par le biais d'une protection partielle du domaine C-terminal de la protéine. Ce domaine C-terminal, caractérisé par deux domaines basiques D1 et D2, est impliqué dans la reconnaissance du récepteur et des HS. Dans ce contexte, nos travaux se sont attachés à définir les aspects structuraux de l'interaction de l'IFNg, et plus précisément de son extrémité C-terminale, avec ses deux ligands. Pour cela, de divers mutants ponctuels, multiples et de délétion de l'IFNg ont été produites, purifiées et étudiées. Leur capacité à lier les HS et le récepteur de l'IFNg est déterminée par SPR puis leur influence sur l'activité antivirale de l'IFNg est déterminée. Les paramètres thermodynamiques de l'interaction IFNg:HS-oligosaccharides sont investigués. Par ailleurs, nous avons préparé une banque oligosaccharidique dérivée d'HS. Le criblage de cette banque, pour sa capacité à lier l'IFNγ, a permis de démontrer que l'IFNg reconnaissait des motifs de sulfatation particuliers. Finalement, nous avons tenté de cristallisé le complexe IFNg:HS-oligosaccharide, jusqu'à présent sans obtention de cristaux qui diffractent. Ces différentes approches visent à élucider le mécanisme de reconnaissance d'IFNg par des HS. Ceci afin de concevoir un mime de ce site d'interaction inhibant la signalisation de l'IFNg. Enfin, une compréhension plus détaillé de l'interaction de l'IFNg avec les HS et son récepteur reste à établir afin d'entièrement comprendre comment l'IFNg migre des HS vers l'IFNgR. / Interferon-γ (IFNγ) is a strong immunomodulating cytokine with some antiviral activity. It has two ligands for which it has high affinities: a receptor through which it transmits its signals, and complex polysaccharides of the heparan sulphate (HS) family. Both are situated on the cellular surface. In vivo, binding on the HS permits local concentration of the cytokine, and regulates its biological activity via a partial protection of the C-terminal region. This C-terminal region, characterised by two basic domains, D1 and D2, is implicated in the recognition of the receptor and the HS. In this context, we investigated the structural features for the interaction of IFNγ, and more specifically the importance of his C-terminus, with both of his cellular ligands. Therefore, we produced, purified and examined various mutants of IFNγ, including points, multiples and deletions mutants. There ability to bind to HS and the IFNγ receptor is examined by SPR and there influence on IFNγ's antiviral activity is determined. The thermodynamics complexation of IFNγ with the HS-oligosaccharides is examined. Moreover, we have prepared an oligosaccharidic library derived from HS. By screening this library for its capacity to bind IFNγ, we have demonstrated that the cytokine recognizes a particular sulphated pattern. Finely, we tried to crystallize the IFNγ:HS-oligosaccharide complex, without obtaining diffracting crystals yet. These studies contribute to clarify the mechanism of recognition of IFNγ by the HS. This would enable us to design a mimic of the interaction site for IFNγ on the HS, who inhibits inappropriate signaling of the cytokine. Finely, a detailed comprehension of the interaction of IFNγ with his receptor and with the HS needs to be established to fully understand how IFNγ migrates for the HS to its receptor.

AN ABSTRACT OF THE DISSERTATION OF Priya Londhe, for the Doctor of Philosophy degree in Biochemistry and Molecular Biology, presented on 30th July, 2013 at Southern Illinois University Carbondale. TITLE: UNRAVELING THE MOLECULAR MECHANISMS OF THE CLASS II TRANSACTIVATOR IN SKELETAL MUSCLE MAJOR PROFESSOR: Dr. Judy Davie The inflammatory cytokine, interferon gamma, IFN-gamma orchestrates a diverse array of fundamental physiological processes and exhibits complex effects on myogenesis. IFN-gamma also induces the class II transactivator, CIITA, which is a critical mediator of IFN-gamma mediated repression and activation. The aims in my dissertation are directed towards understanding the role of IFN-gamma and CIITA in muscle. Stimulation by IFN-gamma in skeletal muscle cells induces CIITA expression as well as MHC class II gene expression. We show that the IFN-gamma induced inhibition of myogenesis is mediated by CIITA, which specifically interacts with myogenin. CIITA acts by both, repressing the expression and inhibiting the activity of myogenin at different stages of myogenesis. The IFN-gamma mediated repression is reversible, with myogenesis proceeding normally upon removal of IFN-gamma. We also show that CIITA is indispensible for the inhibition of myogenesis. To gain a mechanistic insight into the IFN-gamma induced repression of myogenesis, we have discovered that IFN-gamma and CIITA inhibit myogenesis by modifying gene regulation in a muscle cell subject to inflammation. We show that CIITA first interacts with JARID2, a non catalytic subunit of PRC2 complex, which induces a paused RNAPII, phosphorylated at serine 5 and then interacts with the catalytic subunit EZH2, in a JARID2 dependent manner. Our data show that both CIITA and IFN-gamma block myogenesis by the induction and recruitment of the PRC2 complex, which is normally silenced in a differentiating muscle cell. One of my dissertation aims sheds light on the silencing of CIITA in Rhabdomyosarcoma. Silencing of CIITA prevents the expression of MHC Class I and II genes. We have found that IFN-gamma signaling is intact in these cells, but pSTAT1 and IRF1 do not bind to the CIITA PIV promoter. The CIITA promoter is not hypermethylated in RD (ERMS) cells, but shows a modestly enhanced methylation status in SJRH30 (ARMS) cells. We have also observed that histone acetylation, which normally increases on the CIITA PIV promoter following IFN-gamma treatment, is blocked in both types of RMS cells. Further, our studies also impart a novel role for IFN-gamma and CIITA in inhibiting the IGF induced activation of muscle specific genes. Our data show that IFN-gamma does not block the signaling cascade of IGF. However, blocking exogenous IFN-gamma restores IGF activation of muscle specific genes. My dissertation also reveals an important role for the FACT complex in the early steps of gene activation through its histone chaperone activities that serve to open chromatin structure and facilitate transcription promoting muscle differentiation. We show that myogenin interacts with the FACT complex and the recruitment of FACT complex to muscle specific genes is dependent on myogenin. The final aim in my dissertation highlights the distinct binding profiles of the MRFs and E proteins during proliferation and differentiation. Our sequential ChIP assays show that MYOD, MYOG, and MYF5 co-occupy promoters. Taken together, my dissertation provides a comprehensive understanding of the molecular mechanisms during myogenesis and reveals the deleterious effects of chronic inflammation in skeletal muscle.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-11-27T17:22:07Z No. of bitstreams: 1 Andréa Mendes Pereira Ativação de celulas... 2006.pdf: 40276494 bytes, checksum: 9f4656b98e4c74bae9c81e7797e85988 (MD5) / Made available in DSpace on 2012-11-27T17:22:07Z (GMT). No. of bitstreams: 1 Andréa Mendes Pereira Ativação de celulas... 2006.pdf: 40276494 bytes, checksum: 9f4656b98e4c74bae9c81e7797e85988 (MD5) Previous issue date: 2006 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil / Visando avaliar futuramente o potencial de citocinas na indução de resposta imune celular específica do tipo ThI quando associadas a antígeno(s) recombinante(s) de Leishmania chagasi/infantum no cão, a combinação de IL-2 e IL-12 caninas recombinantes é analisada no presente trabalho. Aqui, descrevemos a clonagem do DNA complementar (cDNA) e, pela primeira vez, a expressão de IL-2 canina recombinante biologicamente ativa em Escherichia coli e por células de mamífero. Para expressão em E. coli, utilizou-se a construção pRSET-calL- 2, anteriormente gerada por nosso grupo. Para expressão em células de mamíferos, foi realizada a clonagem do cDNA de IL-2, sintetizado por reação de transcrição reversa seguida de reação da polimerase em cadeia (RT-PCR) a partir do RNA total de células mononucleares do sangue periférico (CMSP) de cão estimuladas com concanavalina A (Con-A), no vetor pcDNAS.l, gerando a construção pcDNA3.1-caIL-2. O sucesso da clonagem em ambos os vetores de expressão foi confirmado a partir do sequenciamento de DNA e comparação dos resíduos de nucleotídeos com a seqüência de IL-2 canina previamente descrita por outro grupo de investigadores. A IL-2 canina recombinante (rcaIL-2) foi obtida como proteína de fiisão contendo cauda de histidina a partir da transformação de E. coli BL21(DE3)pLysS com pRSET- caIL-2, purificada por cromatografia de afinidade e renaturada por diálise. Além disso, a forma nativa de rcaIL-2 foi secretada no sobrenadante de cultura de células COS-7 transfectadas com a construção pcDNA3.1-caIL-2. A atividade proliferativa de rcaIL-2 sobre células CTLL-2 foi demonstrada em concentrações de até 220 pg/mL da citocina purificada a partir da expressão em E. coli e até a diluição de 1:256 do sobrenadante de COS-7 contendo rcaIL-2. A proteína biologicamente ativa foi capaz de manter a proliferação de CMSP de cães sadios por até 12 dias de cultivo quando as células foram tratadas com 50 ng/mL de IL-2 canina obtida de E. coli e por 10 dias com diluições de até 1:200 do sobrenadante de COS-7 contendo a citocina, na ausência de estímulo prévio ou concomitante. A proliferação foi dose-dependente, com ponto máximo ocorrendo no 8° dia de cultivo. A produção de interferon gama (IFN-y) por CMSP de cães sadios estimuladas com sobrenadante de COS-7 contendo IL-2 ou contendo IL-12 não foi significantemente maior que a produção basal. No entanto, um efeito sinérgico sobre a produção in vitro de IFN-y ocorreu quando concentrações subótimas de ambas as citocinas foram associadas. Diante dos resultados obtidos, a construção pcDNA3.1-caIL-2 e ambas as formas de IL-2 canina recombinante obtidas, assim como as condições experimentais aqui descritas, poderão ser utilizadas no futuro para o estudo do potencial de IL-2, associada ou não a IL-12, como modulador da resposta imune in vitro e in vivo de cães, durante o desenvolvimento de uma vacina ou imunoterapia para leishmaniose visceral canina. / Aiming to study in the fiiture the role of cytokines in inducing specific ThI cellular immune response when associated to Leishmania chagasi/infantum recombinant antigen(s) in dogs, the combination of recombinant canine IL-2 and IL-12 is analysed in the present study. Herein, we describe complementary DNA (cDNA) cloning and, for the first time, the expression of biologically active recombinant canine IL-2 in Escherichia coli and mammal cells. The construction pRSET-caIL-2, previously generated by our group, was used for E. coli expression. For mammalian expression, canine IL-2 cDNA was synthesized by reverse transcription followed by polymerase chain reaction (RT-PCR), using cDNA from a healthy dog’s peripheral blood mononuclear cells (PBMC) stimulated with concanavalin A (Con-A) and cloned into pcDNA3.1, generating the construction pcDNA3.1-caIL-2. Success in canine IL-2 cDNA cloning was accessed in both expression vectors by DNA sequencing and was confirmed by comparing nucleotides residues with canine IL-2 sequence previously described by other investigators. Recombinant canine IL-2 (rcaIL-2) was expressed as His-tag fiision protein after E. coli BL21(DE3)pLysS transformation with pRSET-caIL-2, purified by affinity chromatography and renatured through dialysis. In addition, the native form was secreted in culture supematants of pcDNA3.1-caIL-2 transfected COS-7 cells. A proliferative activity was demonstrated in CTLL-2 cells when the recombinant protein was diluted at 220 pg/mL of purified cytokine from E. coli expression or when COS-7 supernatant was diluted at 1:256. The biologically active protein was able to induce proliferation of PBMC of six healthy dogs until 12 days of culture when cells were treated with 50 ng/mL of E. coli expressed-IL-2 or until 10 days when treated with 1:200 COS-7 supernatant dilution containing the cytokine, without previous or concomitant stimulus. The proliferative effect was dose-dependent and maximum at 8th day of culture. Interferon-gamma (IFN-y) production by PBMC of eight healthy dogs induced by COS-7 IL-2 or IL-12-containing supematants was not significantly higher than the baseline production. However, the association of suboptimal concentrations of both cytokines induced synergistic effect upon in vitro IFN-y production by PBMC. Based on the presented results, the construction pcDNA3.1-caIL-2 or both recombinant protein forms obtained, as well as the experimental conditions described here, can be used in the future to evaluate the potential role of IL-2, associated or not to canine IL-12, as a modulator of in vitro and in vivo immune response of dogs during the development of a vaccine or immunotherapy for canine visceral leishmaniasis.

Orientador: Raquel Mantuaneli Scarel Caminaga / Banca: Elisa Maria Aparecida Giro / Banca: Paula Cristina Trevilatto / Resumo: A doença periodontal (DP) em indivíduos com Síndrome de Down (SD) se desenvolve com alta prevalência, precocemente, de modo rápido e generalizado em comparação com indivíduos não-sindrômicos. Foi demonstrado que portadores da SD apresentam resposta imune diminuída em relação aos cromossomicamente normais. O objetivo desta pesquisa foi investigar diferenças nos parâmetros clínicos periodontais e níveis de expressão dos genes Interferon-gama (IFNG), Interferon-gama receptor 1 (IFNGR1), Interferon-gama receptor 2 (IFNGR2), Interferon-alfa (IFNA), Interferon-alfa receptor 1 (IFNAR1), Interferon-alfa receptor 2 (IFNAR2), Janus-quinase 1 (JAK1), Transdutor de sinal e ativador da transcrição 1 (STAT1) e Fator de regulação de interferon 1 (IRF1) em indivíduos com SD que apresentam ou não DP e em indivíduos cromossomicamente normais. Fizeram parte deste estudo 80 indivíduos entre 7 e 57 anos de idade subdivididos em 4 grupos: SD com DP (A); indivíduos com SD sem DP (B); indivíduos não-sindrômicos (Controle) com DP (C) e indivíduos Controle sem DP (D). A expressão gênica foi investigada por meio de quantificação relativa utilizando a técnica da Reação em Cadeia da Polimerase (PCR) em Tempo Real. Para o índice sangramento à sondagem (SS) não houve diferença entre os grupos A e 21 C. A periodontite crônica localizada foi o tipo prevalente tanto entre indivíduos com SD como Controle. Considerando os parâmetros clínicos, não foram encontradas diferenças na periodontite crônica localizada entre os indivíduos com SD e Controle, assim como para a periodontite crônica generalizada. Com relação à análise genética, observou-se que indivíduos dos grupos com SD em relação aos grupos cromossomicamente normais (A+B-C+D) tiveram uma expressão de IFNG semelhante ao observado entre indivíduos do grupo... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Periodontal disease (PD) in individuals with Down Syndrome (DS) has an early, quickly and widespread onset and high prevalence when compared with individuals without the Syndrome. Only poor oral hygiene does not explain the severe periodontal destruction seen in DS patients. It has been shown that DS patients have a weaker immune response than people with normal number of chromosomes. The aim of this study was to investigate differences in periodontal clinical parameters and the expression levels of the genes Interferon-gamma (IFNG), Interferon-gamma receptor 1 (IFNGR1), Interferon-gamma receptor 2 (IFNGR2), interferon-alpha (IFNA), interferon-alpha receptor 1 (IFNAR1), Interferon-alpha receptor 2 (IFNAR2), Janus-kinase 1 (JAK1), Signal transducers and activators of transcription 1 (STAT1) and Interferon regulatory factor 1 (IRF1) in DS patients with and without periodontal disease in comparison with chromossomically normal individuals. A total of 80 individuals aged 7 to 57 years participated in this study and were divided into 4 groups: DS with PD (A); DS without PD (B); individuals without DS (control) with PD (C) and individuals without DS (control) and without PD (D). A quantitative RT-qPCR was used to investigate gene expression. There was no difference between groups A and C regarding the bleeding on probing 25 (BOP) index. The most prevalent type of periodontitis seen in this study was the localized chronic periodontitis, both in individuals with and without DS. Considering the clinical parameters, localized and generalized chronic periodontitis did not differ between individuals with and without DS. Regarding genetic analysis, individuals of the groups with DS in relation to the groups without DS (A+B-C+D) showed an IFNG expression similar to that seen among the individuals of groups control with PD (C-D). However, individuals... (Complete abstract click electronic access below) / Mestre